- Home
- RARE vs NPO Comparison
RARE vs NPO Comparison
Compare RARE & NPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- NPO
- Stock Information
- Founded
- RARE 2010
- NPO 2002
- Country
- RARE United States
- NPO United States
- Employees
- RARE N/A
- NPO N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- NPO Metal Fabrications
- Sector
- RARE Health Care
- NPO Industrials
- Exchange
- RARE Nasdaq
- NPO Nasdaq
- Market Cap
- RARE 3.5B
- NPO 3.9B
- IPO Year
- RARE 2014
- NPO N/A
- Fundamental
- Price
- RARE $36.68
- NPO $193.27
- Analyst Decision
- RARE Strong Buy
- NPO Buy
- Analyst Count
- RARE 15
- NPO 2
- Target Price
- RARE $90.53
- NPO $202.50
- AVG Volume (30 Days)
- RARE 1.1M
- NPO 143.4K
- Earning Date
- RARE 07-31-2025
- NPO 08-05-2025
- Dividend Yield
- RARE N/A
- NPO 0.65%
- EPS Growth
- RARE N/A
- NPO N/A
- EPS
- RARE N/A
- NPO 4.01
- Revenue
- RARE $590,689,000.00
- NPO $1,064,400,000.00
- Revenue This Year
- RARE $18.94
- NPO $4.99
- Revenue Next Year
- RARE $28.93
- NPO $5.27
- P/E Ratio
- RARE N/A
- NPO $47.68
- Revenue Growth
- RARE 33.46
- NPO 2.92
- 52 Week Low
- RARE $29.59
- NPO $133.50
- 52 Week High
- RARE $60.37
- NPO $214.58
- Technical
- Relative Strength Index (RSI)
- RARE 51.86
- NPO 58.90
- Support Level
- RARE $36.03
- NPO $186.38
- Resistance Level
- RARE $37.74
- NPO $191.00
- Average True Range (ATR)
- RARE 1.46
- NPO 4.15
- MACD
- RARE -0.01
- NPO -0.83
- Stochastic Oscillator
- RARE 26.56
- NPO 78.84
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About NPO Enpro Inc.
Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through three segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.